MedTrace Logo

Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg

NCT02550665 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2018-08-07

No results posted yet for this study

Summary

This study evaluates the side effects of dose escalation in the treatment of donepezil 23mg for patients with Alzheimer's disease. Investigators randomly divide participants into three groups according to the dose escalation method; no titration, 15mg of donepezil for a month before escalation to 23mg, and alternating of 10mg and 23mg for a month before escalation to 23mg.

Conditions

Interventions

DRUG

donepezil

using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally

Sponsors & Collaborators

  • Dong-A University

    collaborator OTHER

  • Myongji Hospital

    collaborator OTHER

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Seoul St. Mary's Hospital

    collaborator OTHER

  • Chung-Ang University

    collaborator OTHER

  • Eisai Inc.

    collaborator INDUSTRY

  • Asan Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-08-31
Completion
2016-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02550665 on ClinicalTrials.gov